home.aspx

 
.

DE-RISKY BUSINESS: ASSESSING BIOTHERAPEUTIC OFF-TARGET AND ON-TARGET LIABILITIES

SHARESHARESHARE
De-Risky Business: Assessing Biotherapeutic Off-Target and On-Target Liabilities
Toxicity failures caused by off-target or unintended on-target liabilities are a leading cause of attrition in clinical and preclinical programs. Given the effort, cost, and technical limitations of traditional biopharmaceutical de-risking strategies, there is a need for a robust and scalable approach that can be rapidly applied to the discovery phases of therapeutic programs. Join us for this exciting new GEN Webinar, where our panel of experts will discuss new approaches to de-risking lead selection of antibodies and other biotherapeutics.